Jon's best presentation yet. 1) Presented key information that was interesting to investors pulling information like the breakup of the Trofinetide milestone payments and explanation on the royalties. 2) Answered some good questions giving us insight into topics like FragileX 3) Good update on NNZ-2591 next steps and plans going forward. 4) Good information on the potential market for those 3 indications for NNZ-2591 5) Also good information on how they are looking into other indications for NNZ-2591.
Gave me not just confidence in the portfolio but in the managements focus and strategy..
My personal opinion is they will target additional rare conditions (orphans) for the next indications of NNZ-2591. Whilst dementia is a massive opportunity, Jon clearly stated it comes with big risks, big investment in large multiphase trials.. I think if a partner approached them to do this they would be all over it but not on their own..
NEU Price at posting:
$1.29 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)